New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
08:01 EDTRGLS, FRXRegulus Therapeutics appoints Paul Grint as Chief Medical Officer
Grint joined Regulus from Cerexa, a wholly-owned subsidiary of Forest Laboratories.
News For RGLS;FRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 24, 2014
08:09 EDTRGLSRegulus Therapeutics granted patent for microRNA-103/107 program
Subscribe for More Information
September 18, 2014
08:07 EDTRGLSRegulus Therapeutics initiates ATHENA study in Alport syndrome patients
Regulus Therapeutics has initiated its ATHENA natural history of disease study in patients with Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. The ATHENA study is designed to characterize the natural decline of renal function markers such as Glomerular Filtration Rate, creatinine, proteinuria and beta-2 microglobulin, in Alport syndrome patients over time. The data collected from the ATHENA study will provide information about the changes in renal function over time in Alport syndrome patients, which will inform future clinical development plans of Regulus' RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21, currently in development to treat renal dysfunction in Alport syndrome patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use